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Human cytomegalovirus (CMV) reactivation frequently occurs during the early phase of immune recovery
after allogeneic hematopoietic stem cell transplantation (HSCT). Whereas the recovery of virus-speciﬁc im-
munity in the early phase after HSCT is extensively studied, the impact of CMV on the reconstitution and
composition of the T cell compartment long-term after HSCT is unknown. We analyzed T cell reconstitution
1 to 2 years after HSCT in 131 pediatric patients. One year after HSCT, patients with early CMV reactivation
(n ¼ 46) had 3-fold higher CD8þ T cell numbers (median, 1323 versus 424 cells/mL; P < .0001) compared with
patients without CMV reactivation (n ¼ 85). This effect, caused by a major expansion of CD8þ effector
memory (EM) and end-stage effector (EMRA) T cells, was independent of pretransplantation donor and
recipient CMV serostatus and not seen after Epstein-Barr virus or adenovirus reactivations. At 1 and 2 years
after HSCT, the absolute numbers of CD8þ naive and central memory T cells, as well as CD4þ naive, CM, EM,
and EMRA T cells, did not differ between patients with or without CMV reactivation. In the second year after
HSCT, a signiﬁcant contraction of the initially expanded CD8þ EM and EMRA T cell compartments was
observed in patients with early CMV reactivation. In conclusion, CMV reactivation early after pediatric HSCT
leaves a speciﬁc and dynamic imprint on the size and composition of the CD8þ T cell compartment without
compromising the reconstitution of CD8þ and CD4þ naive and central memory T cells pivotal in the response
to neo and recall antigens.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
In immunocompetent individuals, CMV infection generally
causes mild symptoms, after which latency is established
and asymptomatic reactivations can occur sporadically
throughout life [1]. In contrast, CMV reactivation occurs
frequently during the transient period of immune deﬁciency
after allogeneic hematopoietic stem cell transplantation
(HSCT) in the case of a CMV seropositive donor and/or
recipient. This donor- or recipient-derived CMV infection
or reactivation, hereafter called reactivation, can lead to
disseminated infections, causing interstitial pneumonitis, co-
litis, and hepatitis. Despite the pre-emptive use of antiviral
medication, CMV infections remain a major cause of
morbidity and mortality after HSCT [2,3]. Reconstitution of
CD4þ and CD8þ T cell immunity is pivotal to provide protec-
tion against and achieve sustained control of CMV reac-
tivations [4-6]. In the ﬁrst months after HSCT, the
repopulation of the T cell compartment is facilitated by
cytokine- and antigen-driven homeostatic peripheraldgments on page 661.
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14.01.018expansion of T cells that were transplanted with the graft
[7,8]. The thymic-dependent T cell reconstitution of naive and
central memory cells, essential for a balanced immune system
with a broad speciﬁcity against neo- and recall antigens, is
delayed for many months to years [7].
The differentiation stages of humanTcells can be discerned
based on the expression of cell surface markers CD45RA and
CCR7. Naive (CD45RAþ CCR7þ) cells differentiate upon antigen
exposure into central memory (CM, CD45RA CCR7þ) and
effector memory (EM, CD45RA CCR7) cells and eventually
regain CD45RA when differentiating into end-stage effector
(EMRA, CCR7 CD45RAþ) cells [9]. Whereas the expression of
costimulatory molecules and chemokine receptors varies be-
tween the differentiation stages, ex vivo cytolytic capacity in-
creases during differentiation and telomere length shortens
[9,10]. With increasing age, a continuous accumulation of
CMV-speciﬁc CD8þ T cells, also called memory inﬂation, has
been described in healthy CMV-seropositive individuals. These
cells mainly represent EM and EMRA T cells [11-13]. A durable
expansion of these late differentiated T cells has also been
observed in infants with congenital and postnatal CMV in-
fections [14-17]andafterprimaryCMVinfectionor reactivation
in patients continuously receiving immunosuppressive medi-
cation after solid organ transplantation (SOT) [12,18,19].Transplantation.
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tivations and early immune reconstitution after HSCT has
been the studied extensively [4-6,20,21]. However, apart
from an early report in 1985, the inﬂuence of viral reac-
tivations occurring during the early phase of immune
reconstitution on the composition of the T cell compartment
in steady state conditions after HSCT is largely unknown [22].
In this study, we report the impact of early CMV reactivations
on the reconstitution and composition of the T cell
compartment 1 and 2 years after HSCT in a large cohort of
pediatric HSCT recipients.
METHODS
Ethics Statement
All transplantations were performed according to European Society for
Blood and Marrow Transplantation guidelines. Blood samples were
routinely obtained and analyzed after approval by the institutional review
board (protocol P01.028). Informed consent was provided by the patient
and/or a parent or guardian.
Patients and Blood Sampling
Between January 1, 2002 and December 31, 2011, 227 children received a
bone marrow or peripheral blood stem cell transplantation after myeloa-
blative conditioning for malignant and nonmalignant hematological disor-
ders in the Leiden University Medical Center. A total of 59 patients died in
the ﬁrst year and 11 were lost to follow-up (Figure S1). Of the 157 remaining
patients, 26 were excluded, resulting in a cohort of 131 patients. Exclusion
criteria were relapse of malignant disease (n ¼ 8) or autologous reinfusion
(n ¼ 1) in the ﬁrst year after HSCT, systemic immunosuppressive drugs at 1
year after HSCT (n ¼ 15), or clinically relevant CMV infection after day þ250
(n ¼ 2). Patients who received 2 transplantations (n ¼ 14) were analyzed
only after their second transplantation. Peripheral blood samples were ob-
tained for routine analysis at different time points after HSCTand the sample
drawn closest to 1 year (median, 363 days; range 302 to 478 days) after HSCT
was analyzed in this study. In 76 patients, this sample could be compared
with a sample obtained 2 years (median, 729; range, 498 to 849 days) after
HSCT and at least 180 days after the ﬁrst sample.
Monitoring and Treatment of Viral Reactivations
After HSCT, plasma was routinely screened for Epstein-Barr virus (EBV),
CMV, and human adenovirus (HAdV) DNA by real time quantitative PCR
[23-25]. The limit of detection in these assays was 50 (1.7 log) viral DNA
copies/mL. Reactivation of CMV, EBV, and HAdV was deﬁned as detection of
viral DNA in plasma at least once, whereas pre-emptive treatment with
ganciclovir, rituximab, or cidofovir, respectively, was initiated upon detec-
tion of 1000 (3 log) or more viral DNA copies/mL at 2 or more consecutive
time points [26-28].
Flow Cytometric Analysis
To determine the size of individual lymphocyte populations and subsets,
peripheral blood mononuclear cells (PBMC) were analyzed by ﬂow cytom-
etry. PBMC were separated using ﬁcoll-isopaque density gradient centrifu-
gation (Leiden University Medical Center Pharmacy, Leiden, Netherlands).
PBMC were stained with CD45, CD14, CD33, CD235a, CD3, CD19, CD56, CD4,
CD8, and TCR-gd antibodies, listed in Table S1. Four-color ﬂowcytometry was
performed on a BD FACS Calibur II ﬂow cytometer (Becton Dickinson Bio-
sciences [BD], Franklin Lakes, NJ) and data were analyzed using BD Cellquest
software. Lymphocytes were deﬁned as CD45þ CD33/CD235a/CD14 cells
within the forward/sideward scatter lymphocyte gate and absolute cell
numbers per mL of peripheral blood were calculated. In a representative
subcohort of 53 consecutive patients who underwent transplantation be-
tween 2008 and 2011, T cell differentiation was also analyzed based on
CD45RA and CCR7 expression.
Statistical Analysis
Statistical analysis was performed using SPSS Statistics 20 (IBM SPSS
Inc, Chicago, IL). GraphPad Prism software (version 6.00; GraphPad Soft-
ware, San Diego, CA) was used to construct ﬁgures. Because cell numbers
did not follow Gaussian distribution, Mann-Whitney U test (2 groups),
Kruskall-Wallis test (> 2 groups), and Wilcoxon matched-pairs signed
ranks test (paired analysis) were used for the univariate analysis of nu-
merical parameters. Pearson’s correlation test was performed on log-
transformed data for analysis of univariate correlations. Fisher exact test
(2 groups) and Pearson’s chi-square test (> 2 groups) were used for uni-
variate analysis of categorical parameters. Logistic regression analysis andlinear regression analysis on log-transformed data were performed for
multivariate analysis of parameters with P values  .10 in univariate
analysis.
RESULTS
Incidence of CMV Reactivations and Description of
Patients
In the study cohort of 131 pediatric stem cell trans-
plantation recipients whowere available for follow-up 1 year
after HSCT, 46 patients (35%) experienced a CMV reactivation
in the ﬁrst 100 days after HSCT. The median duration of CMV
viremia was 36 (range, 1 to 185) days, starting 5 to 62 (me-
dian, 26) days after HSCT. The criteria for pre-emptive gan-
ciclovir treatment were met in 33 of 46 patients (Table 1). At
the time of transplantation, patients with CMV reactivation
after HSCT weremore often CMV seropositive (83 versus 31%,
P < .0001) and were older (median, 13.0 versus 7.9 year; P ¼
.001) than patients without CMV reactivation. Also, patients
receiving a graft from a CMV-seropositive donor more often
experienced a CMV reactivation (78 versus 31%, P< .0001). As
shown in Table 1, no signiﬁcant differences were observed in
other HSCT-related parameters. In a logistic regression anal-
ysis of parameters with P values < .10 in univariate analysis,
pretransplantation CMV serostatus of recipient and donor, as
well as patient age, differed signiﬁcantly between children
with and without CMV reactivation after HSCT (P< .0001, P<
.0001, and P ¼ .017, respectively).
Patients with Early CMV Reactivation Had Higher CD8þ T
Cell Numbers One Year after HSCT
Compared with 85 patients without CMV reactivation, 46
patients with early CMV reactivation had signiﬁcantly
higher lymphocyte numbers 1 year after HSCT. This could be
attributed to an increase of CD3þ T cells (median, 2083
versus 1257 cells/mL; P < .0001), whereas NK and B cell
numbers did not differ (Figure 1A). Within the T cell
compartment, absolute CD8þ T cell numbers were 3-fold
higher (median, 1323 versus 424 cells/mL; P < .0001) in pa-
tients with CMV reactivation (Figure 1B). Patients with a low
level CMV reactivation (n ¼ 13), ie, CMV plasma DNA load
above the limit of detection, but not at 2 consecutive time
points above 3.0 log copies/mL, already had signiﬁcantly
higher CD8þ Tcell numbers 1 year after HSCTcomparedwith
patients without CMV reactivation (median, 709 versus 424
cells/mL; P ¼ .0001) (Figure 1C). The highest measured
plasma CMV DNA load and the time between CMV clearance
and analysis at 1 year after HSCT did not inﬂuence the
number of CD8þ T cells at 1 year after HSCT (Figure S2). Also,
the impact of early CMV reactivation on the CD8þ T cell
compartment did not differ between patients who received
a stem cell graft from an HLA-identical related donor,
matched unrelated donor, or haplo-identical donor (data not
shown).
CD4þ T cell numbers were comparable in patients with
and without CMV reactivation (median, 702 versus 684 cells/
mL, P¼ .79) (Figure 1B). Although gd Tcells only represented a
small proportion (median, 4%) of all T cells, gd T cell levels
were 2-fold higher in patients with an early CMV reactivation
(median, 104 versus 47 cells/mL; P ¼ .0005) (Figure 1B).
The Expansion of the CD8þ T Cell Subset was Independent
of Pretransplantation CMV Serostatus and Not Seen after
EBV and HAdV Reactivation
In univariate analysis, CD8þ Tcell numbersdbut not CD4þ
T cell numbers (data not shown)dwere signiﬁcantly
Table 1
Characteristics of Patients with and without Early Cytomegalovirus Reactivation
No CMV Reactivation CMV Reactivation P Value Univariate P Value Multivariate
85 46
Age of recipient (yr) 7.9 (.4-18) 13 (.5-19) .001y .016z
Sex of recipient (male) 56 (66%) 32 (70%) .70x
CMV serostatus of recipient
Positive (anti-CMV IgG) 26 (31%) 38 (83%) < .0001x < .0001z
Age of donor (yr) 24 (2.0-52) 28 (1.0-57) .58y
Sex of donor (male) 43 (51%) 23 (50%) 1.0x
CMV serostatus of donor
Positive (anti-CMV IgG) 26 (31%) 36 (78%) < .0001x < .0001z
Indication for HSCT
Nonmalignant hematology 27 (32%) 21 (46%) .13x
Malignant hematology 58 (68%) 25 (54%)
Donor type
Identical related 35 (41%) 17 (37%) .72{
Haplo-identical 9 (11%) 7 (15%)
Matched unrelated 41 (48%) 22 (48%)
Graft source
Bone marrow 71 (84%) 36 (78%) .48x
Peripheral blood stem cells 14 (17%) 10 (22%)
Conditioning regimen
Total body irradiation based 37 (44%) 18 (39%) .71x
Chemotherapy based 48 (57%) 28 (61%)
Serotherapy
None 23 (27%) 10 (22%) .49{
ATG 53 (63%) 28 (61%)
Alemtuzumab 9 (11%) 8 (17%)
T cell depletion of the graft 9 (11%) 8 (17%) .29x
Donor Lymphocyte Infusion 5 (6%) 2 (4%) 1.0x
Stem Cell Boost 2 (2%) 1 (2%) 1.0x
Acute GVHD  grade 2 13 (15%) 5 (11%) .60x
Peak CMV load
Log copies/mL N.A. 3.8 (2.3-6.0) N.A.
Duration CMV reactivation (day)* N.A. 36 (1-185) N.A.
Start CMV reactivation
First day PCR  1.7 log N.A. 26 (5-62) N.A.
End CMV reactivation
Last day PCR  1.7 log N.A. 80 (13-211) N.A.
Ganciclovir therapy for CMV
DNA load  twice  3 log N.A. 33 (72%) N.A.
EBV reactivation
EBV DNA load  1.7 log 50 (59%) 22 (48%) .20x
Rituximab therapy for EBV
DNA load  twice  3 log 11 (13%) 7 (15%) .79x
HAdV reactivation
HAdV DNA load  1.7 log 20 (24%) 15 (33%) .30x
Cidofovir therapy for HAdV
DNA load  twice  3 log 7 (8%) 2 (4%) .49x
N.A. indicates not applicable; HSCT, hematopoietic stem cell transplantation; CMV, cytomegalovirus; EBV, Epstein-Barr-virus; HAdV, human adenovirus; GVHD,
graft-versus-host-disease, ATG, antithymocyte globulin.
Categorical data are displayed as n (%). Numerical data are displayed as median (range).
* Applied T cell depletion methods: erythrocyte rosetting (n ¼ 2), alemtuzumab in the bag (n ¼ 4) and CliniMACS CD34 enrichment (n ¼ 11).
y Mann-Whitney U test.
z Logistic regression analysis.
x Fisher’s Exact test.
{ Pearson chi-square test.
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versus 424 cells/mL; P < .0001), as well as by pre-
transplantation CMV serostatus of donor (median, 780 versus
460 cells/mL; P < .0001) and recipient (median, 880 versus
440 cells/mL; P < .0001) (Figure S3). However, in multivariate
regression analysis, pretransplantation serostatus of the
donor (P ¼ .22) and recipient (P ¼ .14) did not inﬂuence CD8þ
T cell numbers independently. This is illustrated in Figure 2A,
showing the size of the CD8þ T cell compartment for patients
with and without early CMV reactivation distributed over
the different pretransplantation donor-recipient serostatus
combinations.
EBV or HAdV reactivations, as well as other HSCT-related
variables, including T cell depletion of the graft, serotherapy,
and age of donor and recipient, did not signiﬁcantly inﬂuenceCD8þ T cell numbers 1 year after HSCT (Figure S3). Consid-
ering the high impact of CMV reactivation on the CD8þ T cell
compartment, we separately analyzed the effect of early EBV
and HAdV reactivations in the 85 patients without CMV
reactivation. One year after HSCT, T, B, and NK cell numbers
did not differ between patients with and without EBV or
HAdV reactivations (Figure S4). Also, the size of CD8, CD4,
and gd T cell subsets did not differ between patients with
(n ¼ 50) and without (n ¼ 35) EBV reactivation (Figure 2B).
Patients with HAdV reactivations (n ¼ 20) had lower
numbers of CD8þ T cells and gd T cells than patients (n ¼ 65)
without HAdV reactivation (Figure 2C). However, patients
with and without HAdV reactivations were not fully com-
parable (Table S2). After multivariate correction for alemtu-
zumab serotherapy and T cell depletion of the graft, the
Figure 1. Impact of early CMV reactivation on lymphocyte numbers and subsets 1 year after HSCT. (A) Absolute numbers of lymphocytes, CD3þ T cells, CD3CD19þ B
cells, and CD3CD56þ NK cells and (B) CD8þ T cells, CD4þ T cells, and T cell receptor gdþ T cells from 85 patients without CMV reactivation (white bars, CMV DNA load
always < 1.7 log copies/mL [c/mL]) and 46 patients with CMV reactivation (gray bars, CMV DNA load  1x >1.7 log). (C) Absolute numbers of CD8þ T cells of 85
patients without detectable CMV reactivation (white bars), 13 patients with detectable CMV DNA in plasma but not  3 log c/mL at 2 consecutive time points (light
gray bars) and 33 patients with a CMV load  3 log c/mL at 2 or more consecutive time points (dark gray bars). Shown are cells/mL of peripheral blood 1 year after
HSCT. Bars: median, interquartile range and overall range. P values: Mann-Whitney test; NS indicates P > .05; ***P < .001; **** P < .0001.
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year after HSCT was not statistically signiﬁcant (P ¼ .11).The Increase of CD8þ T Cells after CMV Reactivation was
Caused by an Expansion of EM and EMRA Cells
In a subcohort of 53 consecutive patients who underwent
transplantation between 2008 and 2011, we further deter-
mined the differentiation stages of CD4þ and CD8þ T cells.
Patients in this subcohort did not differ signiﬁcantly from the
whole cohort with respect to the parameters listed in Table 1
(data not shown). In both T cell subsets, but most pro-
nounced in the CD8þ T cell subset, the proportion of effector
memory and end-stage effector T cells were enlarged in pa-
tients with (n¼ 18) compared with patients without (n¼ 35)
early CMV reactivation. Together, the cells of the EM and
EMRA phenotype constituted a median of 88% of the CD8þ T
cell subset in patients with early CMV reactivation compared
with 55% in patients without CMV reactivation (P < .0001)
(Figure 3A).
Next, we calculated absolute cell numbers for the T cell
differentiation stages. The altered memory differentiation inFigure 2. Inﬂuence of pretransplantation CMV serostatus and early EBV and HAdV rea
on CD8þ T cell numbers in patients without CMV reactivation (white bars, þ/þ: n ¼ 14
(gray bars, þ/þ: n ¼ 28, þ/: n ¼ 8 and /þ, n ¼ 10). (B & C) Absolute numbers of
reactivation. (B) Shows 35 patients without versus 50 patients with early Epstein-Barr
with early human adenovirus (HAdV) reactivation. White bars (): plasma DNA load a
are cells/mL of peripheral blood 1 year after HSCT. Bars: median, interquartile range an
NS indicates P > .05; *P < .05.the CD8þ Tcell subset in patients with early CMV reactivation
was caused by a major expansion of CD8þ EM and EMRA T
cells (median, 485 versus 141; P < .0001 and 509 versus 114
cells/mL; P < .0001) (Figure 3A). The size of the CD8þ naive
and CM T cell compartments were not signiﬁcantly affected
by early CMV reactivation. The increased contribution of
CD4þmemory T cells in patients with early CMV reactivation
was caused by a nonsigniﬁcant increase of CD4þ and EMRA T
cells and a nonsigniﬁcant reduction of CD4þ naive and CM T
cell numbers (Figure 3B).Dynamics of CD8þ T Cell Expansion in Patients with Early
CMV Reactivation after HSCT
For the 46 patients with an early CMV reactivation, we
categorized patients based on the size of the primary CD8þ T
cell recovery at the moment of CMV clearance. In patients
with CD8þ T cell numbers < 500 cells/mL at the moment of
CMV clearance (n ¼ 21), the CD8þ T cell number gradually
increased after the clearance of CMV (Figure 4A). In contrast,
in patients with CD8þ T cell numbers > 500 cells/mL at the
moment of CMV clearance (n ¼ 25), this subset did notctivation. (A) Impact of donor and recipient pretransplantation CMV serostatus
, þ/: n ¼ 12, /þ: n ¼ 13 and /: n ¼ 46) and patients with CMV reactivation
CD3þ, CD4þ, CD8þ, and T cell receptor gdþ T cell in 85 patients without CMV
virus (EBV) reactivation and (C) shows 65 patients without versus 20 patients
lways < 1.7 log. Gray bars (þ): plasma DNA load at least once > 1.7 log. Shown
d overall range, P values: Kruskall-Wallis test (A) or Mann-Whitney test (B & C).
Figure 3. Early CMV reactivation and T cell differentiation one year after HSCT. Absolute numbers (left panels) and relative contribution (right panels) of T cell
differentiation stages to the (A) CD8þ and (B) CD4þ T cell subsets in a subcohort of 35 patients without () and 18 patients with (þ) CMV reactivation. N: naive (very
light gray, CD45RAþ CCR7þ), CM: central memory (light gray, CD45RA CCR7þ), EM: effector memory (gray, CD45RA CCR7-), EMRA (dark gray, CD45RAþ CCR7).
Absolute numbers: shown are cells/mL of peripheral blood 1 year after HSCT. Bars: median, interquartile range and overall range. P values: Mann-Whitney test; NS
indicates P >.05; ****P < .0001. Relative contribution: bars show mean percentage of the CD8þ or CD4þ T cell subset with standard error of the mean.
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CD8þ T cell number was not inﬂuenced by T cell depletion of
the graft (Figure S3), all patients (n ¼ 8) who received a T
celledepleted graft had CD8þ T cell numbers < 500 cells/mL
at the moment of CMV clearance (P ¼ .001) (Table S3).
Although the dynamics of the CD8þ T cell expansion differed,
the size and composition of the CD8þ Tcell compartment at 1
year after HSCT were comparable between patients with
high or low CD8þ T cell numbers at the time of CMV clear-
ance (Figure 4B).
Ongoing Reconstitution of Naive and CM Cells in Parallel
with Contraction of EM and EMRA CD8þ T Cells in the
Second Year after HSCT
Finally, we investigated the inﬂuence of early CMV reac-
tivations on the T cell reconstitution in the second year after
HSCT. The number of CD8þ T cells decreased in patients with
early CMV reactivation (n ¼ 34; median, 1340 to 1141 cells/
mL; P¼ .010), whereas an increase in CD8þ Tcell numbers was
seen in patients without CMV reactivation (n ¼ 42; median
473 to 619 cells/mL; P¼ .043) (Figure 5A). Still, the CD8þ T cell
number at 2 years after HSCT remained signiﬁcantly higher
in patients with early CMV reactivation (P ¼ .0002). In both
groups, CD4þ T cell numbers increased in the second year
after HSCT.
More profound changes were observed in the separate T
cell differentiation compartments in a subcohort of 31 HSCT
recipients who underwent transplantation between 2008
and 2010. In patients with early CMV reactivation (n ¼ 12), a
contraction of late differentiated CD8þ EM (median, 825
to 618; P¼ .0068) and EMRATcells (median, 555 to 378 cells/Figure 4. Dynamics of CD8þ T cell reconstitution in patients with early CMV reactiva
primary CD8þ T cell recovery < 500 cells/mL and 25 patients with a primary recovery
clearance (C), .5 year and 1 year after HSCT. Bars: median, interquartile range and o
signed rank test. NS indicates P >.05; ***P < .001; ****P < .0001. (B) Absolute numb
mary CD8þ T cell recovery< 500 cells/mL and 9 patients with a primary recovery> 500
gray, CD45RA CCR7þ), EM: effector memory (gray, CD45RA CCR7), EMRA (dark gr
Bars: median, interquartile range and overall range. P values: Mann-Whitney test; NmL; P ¼ .0342) was observed. This was accompanied by
a further reconstitution of CD8þ naive and CM T cells
(Figure 5B). In patients without CMV reactivation (n ¼ 19),
CD8þ naive and CM cell numbers increased, whereas the size
of the CD8þ EM and EMRA compartments remained stable
over time. The increase of CD4þ Tcell numbers was caused by
an expansion of naive and CM cells both in patients with and
without early CMV reactivation (Figure 5C).
DISCUSSION
Here, we provide evidence that early and transient CMV
reactivation leaves a long-lasting, dynamic, and speciﬁc
signature on the composition of the T cell compartment in
pediatric HSCT recipients. One year after transplantation,
patients who had encountered (and cleared) early CMV
reactivation showed a marked relative as well as absolute
expansion of the CD8þ EM and EMRA T cell populations. This
typical pattern was not seen in patients with early EBV or
HAdV reactivation, and early CMV reactivation did not
compromise the reconstitution of the naive and CM com-
partments. Furthermore, the CMV signature on T cell
reconstitution was subjected to dynamic changes in the year
thereafter. This throws a new light on the early ﬁndings by
Würsch et al. in 1985, describing the impact of early CMV
infection on the developing T cell immunity in adult HSCT
recipients [22].
One year after HSCT, none of the patients included in this
study had active CMV infection. Also, pretransplantation
CMV seropositivity of donor or recipient without detectable
CMV viremia after HSCT did not trigger the expansion of
CD8þ T cells. Therefore, we hypothesize that CMVtion. (A) CD8þ T cell reconstitution after CMV clearance in 21 patients with a
> 500 cells/mL. Shown are cells/mL of peripheral blood at the moment of CMV
verall range. Lines connect median values. P values: Wilcoxon matched-pairs
ers of T cell differentiation stages 1 year after HSCT in 9 patients with a pri-
cells/mL. N: naive (very light gray, CD45RAþ CCR7þ), CM: central memory (light
ay, CD45RAþ CCR7). Shown are cells/mL of peripheral blood 1 year after HSCT.
S indicates P > .05; *P < .05.
Figure 5. Dynamics of T cell reconstitution 1 and 2 years after HSCT. (A) Paired analysis of absolute numbers of CD8þ and CD4þ T cells in 42 patients without and 34
patients with early CMV reactivation at 1 and 2 years after HSCT. Shown are cells/mL of peripheral blood 1 and 2 years after HSCT. (B & C) Paired analysis of absolute
numbers of (B) CD8þ and (C) CD4þ N, CM, EM, and EMRA T cells in 19 patients without () and 12 patients with (þ) CMV reactivation at 1 and 2 years after HSCT.
N: naive (very light gray, CD45RAþ CCR7þ), CM: central memory (light gray, CD45RA CCR7þ), EM: effector memory (gray, CD45RA CCR7), EMRA (dark gray,
CD45RAþ CCR7). Shown are cells/mL of peripheral blood 1 and 2 years after HSCT. Bars (A): median, interquartile range and overall range. Diamonds (B & C): Median
and interquartile range. Lines connect median values 1 and 2 years after HSCT. Arrows ([/Y): increase/reduction. P values: Wilcoxon matched-pairs signed rank test.
¼ indicates P > .10; NS, .05 < P < .10; *P < .05; **P < .01; ****P < .0001.
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early after HSCT leads to infection of large numbers of cells,
which remain infected latently and can lead to subclinical
reactivations, providing antigenic stimulus for the ongoing
expansion and differentiation of CMV-speciﬁc T cells in a
proinﬂammatory environment [7,8,29,30]. This proceeds
after discontinuation of immunosuppressive medication
after HSCT and is most evidently observed in patients with
a relatively small number of CD8þ T cells at the moment
of CMV clearance. However, the relative contribution of
peripherally expanded memory cells, which have been
transplanted with the graft, and differentiated, newly
educated naive T cells to the pool of CD8þ EM and EMRA T
cells is not known [7,8]. Although our observations do not
allow for a deﬁnitive conclusion about the speciﬁcity of the
expanded CD8þ T cells, the differentiation of virus-speciﬁc T
cells has been studied extensively. CMV-speciﬁc CD8þ T cells
are mainly of the late differentiated EM and EMRA pheno-
types. Especially the EMRA phenotype is more often seen in
the context of CMV compared with other viruses [11,12,31].
Of note, T cell exhaustion, characterized by the upregulation
of inhibitory receptors, such as PD-1, and the progressive loss
of cytokine production, proliferative capacity, and cytolytic
function [32] has not been found applicable for CMV-speciﬁc
T cells [33-35].
CD4þ T cells are essential for the maintenance of CMV-
speciﬁc CD8þ T cell responses and can also acquire direct
cytolytic capacity [36-38]. Indeed, 1 and 2 years after HSCT, a
minor but stable expansion of CD4þ T cells of the late EMRA
phenotype was found in patients with early CMV reac-
tivation. More profound changes were present in the gd-T
cell subset. Their role in CMV clearance has been well
established and these cells can compose up to 30% of T cells
at the time of CMV clearance [39,40].
We show that, although their relative contribution to the
respective T cell subsets was decreased, the numerical
reconstitution of naive and central memory cells in both the
CD8þ and the CD4þ T cell subset was not negatively affected
by early CMV reactivation. This indicates that thymic output
and the generation of a central memory compartment are not
disturbed. The reconstitution of early differentiated T cells is
essential for a healthy and balanced adaptive immune system
with the capacity to produce cellular immune responses
against neo and recall antigens [7]. However, in contrast to the
evaluation of recall vaccination responses, the evaluation of T
cell responses against neoantigens is very difﬁcult. Still, thishypothesis is supported by the observation that the memory
compartment is ﬂexible and expansion of CMV-speciﬁc
memory cells does not result in lower numbers of EBV- and
inﬂuenza-speciﬁc T cells after SOT [31]. Furthermore, the
accumulation of late differentiated CMV-speciﬁcmemory cells
has not been observed in lymph nodes, leaving immunologic
space for the generation of new immune responses [41].
CMV reactivation in adult SOT recipients receiving life-
long immunosuppressive medication has been correlated
to an accelerated and ongoing accumulation of late differ-
entiated T cells with a stable (relative) contribution of CMV
speciﬁc T cells [19,30,42]. Although the number of CD8þ T
cells expanded after CMV clearance in pediatric HSCT re-
cipients with a small primary CD8þ T cell response, a stable
condition was reached early after transplantation in children
with high CD8þ T cell numbers at the moment of CMV
clearance. Also, we did not observe a further expansion of
memory cells in the second year after HSCT. We even noticed
a reduction of the CD8þ EM and EMRA compartment in
childrenwith early CMV reactivations. The SOT setting differs
fundamentally from HSCT, because in HSCT recipients, CMV
reactivations occur in a newly reconstituting immune sys-
tem. Furthermore, in our cohort, immunosuppression was
tapered 3 to 6 months after transplantation, whereas SOT
recipients receive life-long immunosuppressive medication.
We compared our results to reported ﬁndings in a more
physiological setting of CMV infection in healthy Gambian
infants as well. One year after infection, the proportion of
late differentiated CD8þ T cells was much smaller (mean,
17%) in CMV-infected infants than in our cohort. Similar to
our data after HSCT, the relative contribution of these cells to
the CD8þ T cell compartment decreased slightly in the sec-
ond year after infection [16,17]. Although no absolute cell
numbers were assessed in these studies, the differencemight
be explained by a large contribution of naive T cells in infants
compared with pediatric HSCT recipients, as well as the
severity of the CMV infection after HSCT, as discussed above.
Although we analyzed T cell reconstitution in a large
cohort of HSCT recipients, the size and diversity of the sub-
cohort of patients with a hematological malignancy did not
allow for a reliable evaluation of the impact of early CMV
reactivation on the relapse risk [43]. Also, extended follow-
up is required to evaluate the impact of early CMV reac-
tivation on long-term clinical outcome. One year after HSCT,
the phenotype of the CD8þ T cell subset of pediatric HSCT
recipients with early CMV reactivation closely resembled
G. Lugthart et al. / Biol Blood Marrow Transplant 20 (2014) 655e661 661that of the CD8þ T cells of elderly CMV-seropositive in-
dividuals [13]. However, the expansion of naive and CM cells,
together with a dynamic contraction of the CD8þ late
differentiated memory T cell compartment in the second
year after HSCT, imply that an ongoing process of immune
regulation and further reconstitution is operative in
modeling the cellular immune system after discontinuation
of immunosuppressive medication. Altogether, CMV reac-
tivation early after HSCT leads to a dynamic expansion of late
differentiated CD8þ T cells on top of a normal reconstitution
of the naive and central memory compartment.
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